Stephen Garbacz
Corporate Officer/Principal chez Tessera Therapeutics, Inc.
Profil
Stephen Garbacz is currently the Head of Finance at Tessera Therapeutics, Inc. He previously worked as the CAO and Executive Director of Finance at Epizyme, Inc. in 2012.
From 2019 to 2021, he was the Vice President of Finance and Corporate Controller at Anika Therapeutics, Inc. Prior to that, he was the Senior Vice President of Finance and Operations at Spero Therapeutics, Inc. Mr. Garbacz received his undergraduate degree from George Mason University and his MBA from The Leonard N Stern School of Business.
Postes actifs de Stephen Garbacz
| Sociétés | Poste | Début |
|---|---|---|
Tessera Therapeutics, Inc.
 Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/05/2021 |
Anciens postes connus de Stephen Garbacz
| Sociétés | Poste | Fin |
|---|---|---|
| ANIKA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/05/2021 |
| SPERO THERAPEUTICS, INC. | Directeur des opérations | - |
| EPIZYME, INC. | Directeur Financier/CFO | - |
Formation de Stephen Garbacz
| The Leonard N Stern School of Business | Masters Business Admin |
| George Mason University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SPERO THERAPEUTICS, INC. | Health Technology |
| ANIKA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Health Technology |